Cargando…

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

Detalles Bibliográficos
Autores principales:	Patel, Shruti R., Neal, Joel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413020/ https://www.ncbi.nlm.nih.gov/pubmed/37577327 http://dx.doi.org/10.21037/tlcr-23-273

Ejemplares similares

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
por: Verhoek, Andre, et al.
Publicado: (2023)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
por: Gridelli, Cesare, et al.
Publicado: (2020)

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
por: Cortellini, Alessio, et al.
Publicado: (2020)

Is bronchoalveolar lavage a game changer in the diagnosis of interstitial lung disease?
por: Singh, Sheetu, et al.
Publicado: (2016)

Reflecting on ICN2: was it a game changer?
por: Brinsden, Hannah, et al.
Publicado: (2015)

Commentary: Artificial intelligence–A game changer
por: Ahuja, Ashish, et al.
Publicado: (2020)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

New Insights into the Epigenomic Landscape of Small-Cell Lung Cancer: A Game Changer?
por: Sarode, Poonam, et al.
Publicado: (2022)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
por: Patel, Sandip, et al.
Publicado: (2023)

Commentary: Nearwork-induced transient myopia – Is this the game changer?
por: Narang, Purvasha
Publicado: (2021)

Vitamin K in CKD: A Game-Changer or By-Stander
por: Krishnasamy, Rathika, et al.
Publicado: (2023)

Digital health: a game changer
Publicado: (2019)

Chlorhexidine for umbilical cord care: game-changer for newborn survival?
por: Hodgins, Steve, et al.
Publicado: (2013)

The progressive intellectual and neurological deterioration study: a game changer
por: van Karnebeek, Clara DM
Publicado: (2020)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

Cost‐effectiveness of osimertinib versus placebo in resected EGFR‐mutated non‐small cell lung cancer in China
por: Zhou, Xiwen, et al.
Publicado: (2022)

Dexmedetomidine: The game changer or a team player?
por: Goyal, Rakhee
Publicado: (2016)

Flu RNA Vaccine: A Game Changer?
por: Meurens, François
Publicado: (2020)

Refractive surgery – the 20/happy game changer
por: Honavar, Santosh G
Publicado: (2020)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Commentary: Big data in Ophthalmology: A big game changer on horizon
por: Kumar, Nilesh, et al.
Publicado: (2021)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2015)

Game Changers
Publicado: (2015)

Game changers
Publicado: (2016)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Gonococcal Vaccines for Controlling Neisseria gonorrhoeae in Men Who Have Sex With Men: A Promising Game Changer
por: Christensen, Hannah, et al.
Publicado: (2021)

Heading for trouble: is dementia a game changer for football?
por: Rutherford, A, et al.
Publicado: (2019)

Ten game-changers in mental health for South Africa
por: Stein, Dan J., et al.
Publicado: (2023)

High Endothelial Venules and Pancreatic Ductal Adenocarcinoma: A potential game changer
por: Chai, Shu Ming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_84hgkrbaupqfkinppebj7jh3hl